418 related articles for article (PubMed ID: 2159380)
21. Effect of phorbol ester treatment on drug-induced, topoisomerase II-mediated DNA cleavage in human leukemia cells.
Zwelling LA; Chan D; Hinds M; Mayes J; Silberman LE; Blick M
Cancer Res; 1988 Dec; 48(23):6625-33. PubMed ID: 2846155
[TBL] [Abstract][Full Text] [Related]
22. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
Poddevin B; Riou JF; Lavelle F; Pommier Y
Mol Pharmacol; 1993 Oct; 44(4):767-74. PubMed ID: 8232227
[TBL] [Abstract][Full Text] [Related]
23. ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors.
Holm B; Jensen PB; Sehested M
Cancer Chemother Pharmacol; 1996; 38(3):203-9. PubMed ID: 8646793
[TBL] [Abstract][Full Text] [Related]
24. Embryotoxicity of the intercalating agents m-AMSA and o-AMSA and the epipodophyllotoxin VP-16 in postimplantation rat embryos in vitro.
Mirkes PE; Zwelling LA
Teratology; 1990 Jun; 41(6):679-88. PubMed ID: 2162085
[TBL] [Abstract][Full Text] [Related]
25. Development and properties of an etoposide-resistant human leukaemic CCRF-CEM cell line.
Patel S; Austin CA; Fisher LM
Anticancer Drug Des; 1990 Feb; 5(1):149-57. PubMed ID: 2156515
[TBL] [Abstract][Full Text] [Related]
26. Aclarubicin inhibits etoposide induced apoptosis through inhibition of RNA synthesis in P388 murine leukemic cells.
Nagata T; Higashigawa M; Shimono Y; Cao DC; Yan Mao X; M'soka T; Inamochi H; Hori H; Kawasaki H; Sakurai M
J Exp Clin Cancer Res; 1998 Dec; 17(4):435-42. PubMed ID: 10089064
[TBL] [Abstract][Full Text] [Related]
27. Topoisomerase II-dependent and -independent mechanisms of etoposide resistance in Chinese hamster cell lines.
Spiridonidis CA; Chatterjee S; Petzold SJ; Berger NA
Cancer Res; 1989 Feb; 49(3):644-50. PubMed ID: 2535964
[TBL] [Abstract][Full Text] [Related]
28. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
29. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y
Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973
[TBL] [Abstract][Full Text] [Related]
30. Effect of cell proliferation and chromatin conformation on intercalator-induced, protein-associated DNA cleavage in human brain tumor cells and human fibroblasts.
Zwelling LA; Estey E; Silberman L; Doyle S; Hittelman W
Cancer Res; 1987 Jan; 47(1):251-7. PubMed ID: 3024817
[TBL] [Abstract][Full Text] [Related]
31. Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II.
Cole SP; Chanda ER; Dicke FP; Gerlach JH; Mirski SE
Cancer Res; 1991 Jul; 51(13):3345-52. PubMed ID: 1675932
[TBL] [Abstract][Full Text] [Related]
32. Altered subcellular distribution of topoisomerase II alpha in a drug-resistant human small cell lung cancer cell line.
Feldhoff PW; Mirski SE; Cole SP; Sullivan DM
Cancer Res; 1994 Feb; 54(3):756-62. PubMed ID: 8306338
[TBL] [Abstract][Full Text] [Related]
33. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES
Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806
[TBL] [Abstract][Full Text] [Related]
34. Phorbol ester effects on topoisomerase II activity and gene expression in HL-60 human leukemia cells with different proclivities toward monocytoid differentiation.
Zwelling LA; Hinds M; Chan D; Altschuler E; Mayes J; Zipf TF
Cancer Res; 1990 Nov; 50(22):7116-22. PubMed ID: 2171756
[TBL] [Abstract][Full Text] [Related]
35. Hyperthermia can reduce cytotoxicity from etoposide without a corresponding reduction in the number of topoisomerase II-DNA cleavable complexes.
Dynlacht JR; Wong RS; Albright N; Dewey WC
Cancer Res; 1994 Aug; 54(15):4129-37. PubMed ID: 8033146
[TBL] [Abstract][Full Text] [Related]
36. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
Jensen LH; Dejligbjerg M; Hansen LT; Grauslund M; Jensen PB; Sehested M
BMC Pharmacol; 2004 Dec; 4():31. PubMed ID: 15575955
[TBL] [Abstract][Full Text] [Related]
37. The combination of different types of antitumor topoisomerase II inhibitors, ICRF-193 and VP-16, has synergistic and antagonistic effects on cell survival, depending on treatment schedule.
Ishida R; Iwai M; Hara A; Andoh T
Anticancer Res; 1996; 16(5A):2735-40. PubMed ID: 8917380
[TBL] [Abstract][Full Text] [Related]
38. Production of protein-associated DNA breaks by 10-[diethylaminopropylamino]-6-methyl-5H-pyrido[3',4':4,5]pyrrolo [2,3-g]isoquinoline in cultured L1210 cells and in isolated nuclei: comparison with other topoisomerase II inhibitors.
Pierson V; Pierre A; Pommier Y; Gros P
Cancer Res; 1988 Mar; 48(6):1404-9. PubMed ID: 2830964
[TBL] [Abstract][Full Text] [Related]
39. Relative activity of structural analogues of amsacrine against human leukemia cell lines containing amsacrine-sensitive or -resistant forms of topoisomerase II: use of computer simulations in new drug development.
Zwelling LA; Mitchell MJ; Satitpunwaycha P; Mayes J; Altschuler E; Hinds M; Baguley BC
Cancer Res; 1992 Jan; 52(1):209-17. PubMed ID: 1309224
[TBL] [Abstract][Full Text] [Related]
40. DNA topoisomerase: the mechanism of resistance to DNA topoisomerase II inhibitor VP-16.
Hong JH
Hiroshima J Med Sci; 1989 Dec; 38(4):197-207. PubMed ID: 2561562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
